{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:33:36Z","timestamp":1789122816494,"version":"build-2803163510"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":24,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jtct.2026.08.015","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T23:36:00Z","timestamp":1787096160000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hematopoietic Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm: Clinical Practice Guidelines From the American Society for Transplantation and Cellular Therapy"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7394-5185","authenticated-orcid":false,"given":"Mohamed A.","family":"Kharfan-Dabaja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambuj","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen","family":"Pemmaraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4534-4248","authenticated-orcid":false,"given":"Hemant","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monzr","family":"Al Malki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qaiser","family":"Bashir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Bubis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew A.","family":"Lane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiga","family":"Nishihori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8568-4522","authenticated-orcid":false,"given":"Marcos","family":"de Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naseema","family":"Gangat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2411-4742","authenticated-orcid":false,"given":"Omer","family":"Jamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9347-2212","authenticated-orcid":false,"given":"Marina","family":"Konopleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selina","family":"Luger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3304-9965","authenticated-orcid":false,"given":"Bipin","family":"Savani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendra","family":"Sweet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jtct.2026.08.015_bib0001","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1097\/00000478-200207000-00003","article-title":"'Agranular CD4+ CD56+ hematodermic neoplasm' (blastic NK-cell lymphoma) originates from a population of CD56+ precursor cells related to plasmacytoid monocytes","volume":"26","author":"Petrella","year":"2002","journal-title":"Am J Surg Pathol"},{"issue":"10","key":"10.1016\/j.jtct.2026.08.015_bib0002","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1182\/blood.V97.10.3210","article-title":"Identification of a leukemic counterpart of the plasmacytoid dendritic cells","volume":"97","author":"Chaperot","year":"2001","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2026.08.015_bib0003","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s11596-021-2393-3","article-title":"Plasmacytoid dendritic cell neoplasm: progress in cell origin, molecular biology, diagnostic criteria and therapeutic approaches","volume":"41","author":"Cheng","year":"2021","journal-title":"Curr Med Sci"},{"issue":"7","key":"10.1016\/j.jtct.2026.08.015_bib0004","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.jtct.2026.08.015_bib0005","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2026.08.015_bib0006","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3324\/haematol.2012.072645","article-title":"Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study","volume":"98","author":"Pagano","year":"2013","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.jtct.2026.08.015_bib0007","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1182\/blood.2024024262","article-title":"How I treat blastic plasmacytoid dendritic cell neoplasm","volume":"145","author":"Kharfan-Dabaja","year":"2025","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.jtct.2026.08.015_bib0008","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1182\/bloodadvances.2019000647","article-title":"How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?","volume":"3","author":"Garnache-Ottou","year":"2019","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.jtct.2026.08.015_bib0009","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1007\/s00277-023-05587-7","article-title":"Diagnostic management of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in close interaction with therapeutic considerations","volume":"103","author":"Shumilov","year":"2024","journal-title":"Ann Hematol"},{"issue":"15","key":"10.1016\/j.jtct.2026.08.015_bib0010","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1182\/blood.2021011817","article-title":"Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm","volume":"138","author":"Pemmaraju","year":"2021","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jtct.2026.08.015_bib0011","doi-asserted-by":"crossref","first-page":"10174","DOI":"10.18632\/oncotarget.7101","article-title":"Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy","volume":"7","author":"Martin-Martin","year":"2016","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.jtct.2026.08.015_bib0012","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1080\/10428194.2022.2090552","article-title":"Treatment patterns and outcomes of patients with CNS involvement of blastic plasmacytoid dendritic cell neoplasm (BPDCN)","volume":"63","author":"Davis","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtct.2026.08.015_bib0013","unstructured":"National Comprehensive Cancer Network. Acute myeloid leukemia.https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/aml.pdf. Accessed April 23, 2026."},{"issue":"10","key":"10.1016\/j.jtct.2026.08.015_bib0014","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1182\/bloodadvances.2021006645","article-title":"Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD","volume":"6","author":"Pemmaraju","year":"2022","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.jtct.2026.08.015_bib0015","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/sj.bmt.1704215","article-title":"What is CD4+CD56+ malignancy and how should it be treated?","volume":"32","author":"Reimer","year":"2003","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2026.08.015_bib0016","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/bjh.14146","article-title":"Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches","volume":"174","author":"Pagano","year":"2016","journal-title":"Br J Haematol"},{"issue":"14","key":"10.1016\/j.jtct.2026.08.015_bib0017","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1182\/bloodadvances.2020001875","article-title":"Survival outcomes in blastic plasmacytoid dendritic cell neoplasm by first-line treatment and stem cell transplant","volume":"4","author":"Yun","year":"2020","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.jtct.2026.08.015_bib0018","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1182\/blood.2019001144","article-title":"Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark","volume":"134","author":"Taylor","year":"2019","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.jtct.2026.08.015_bib0019","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14153767","article-title":"Conventional therapeutics in BPDCN patients-do they still have a place in the era of targeted therapies?","volume":"14","author":"Poussard","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"17","key":"10.1016\/j.jtct.2026.08.015_bib0020","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1056\/NEJMoa1815105","article-title":"Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm","volume":"380","author":"Pemmaraju","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jtct.2026.08.015_bib0021","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1200\/JCO-25-02083","article-title":"Pivekimab sunirine in blastic plasmacytoid dendritic cell neoplasm","volume":"44","author":"Pemmaraju","year":"2026","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2026.08.015_bib0022","doi-asserted-by":"crossref","first-page":"E62","DOI":"10.1002\/ajh.26417","article-title":"Venetoclax and hypomethylating agents in older\/unfit patients with blastic plasmacytoid dendritic cell neoplasm","volume":"97","author":"Gangat","year":"2022","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.jtct.2026.08.015_bib0023","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1182\/blood.2022017865","article-title":"North American blastic plasmacytoid dendritic cell neoplasm consortium: position on standards of care and areas of need","volume":"141","author":"Pemmaraju","year":"2023","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2026.08.015_bib0024","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1182\/blood-2012-08-448613","article-title":"Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation","volume":"121","author":"Roos-Weil","year":"2013","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.jtct.2026.08.015_bib0025","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1182\/blood-2015-01-621268","article-title":"Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm","volume":"125","author":"Aoki","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jtct.2026.08.015_bib0026","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/bjh.14954","article-title":"Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study","volume":"179","author":"Kharfan-Dabaja","year":"2017","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.jtct.2026.08.015_bib0027","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1182\/blood-2016-09-726653","article-title":"Can a reduced-intensity conditioning regimen cure blastic plasmacytoid dendritic cell neoplasm?","volume":"129","author":"Leclerc","year":"2017","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.jtct.2026.08.015_bib0028","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1080\/10428194.2022.2118531","article-title":"Allogeneic hematopoietic stem cell transplantation with myeloablative conditioning regimen for blastic plasmacytoid dendritic cell neoplasm patients in complete remission: a single center study","volume":"63","author":"Lu","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.jtct.2026.08.015_bib0029","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41409-021-01478-5","article-title":"Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN)","volume":"57","author":"Bashir","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2026.08.015_bib0030","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41375-022-01782-z","article-title":"Retrospective analysis of hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: conditioning intensity matters","volume":"37","author":"Bruch","year":"2023","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.jtct.2026.08.015_bib0031","doi-asserted-by":"crossref","first-page":"7007","DOI":"10.1182\/bloodadvances.2023011308","article-title":"Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis","volume":"7","author":"Murthy","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2026.08.015_bib0032","article-title":"Allogeneic hematopoietic cell transplantation as the standard of care for blastic plasmacytoid dendritic cell neoplasm in first complete remission","author":"MA","year":"2025","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"11","key":"10.1016\/j.jtct.2026.08.015_bib0033","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.clml.2018.07.295","article-title":"Allogeneic Hematopoietic Cell Transplantation Is an Effective Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm in First Complete Remission: Systematic Review and Meta-analysis","volume":"18","author":"Kharfan-Dabaja","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"13","key":"10.1016\/j.jtct.2026.08.015_bib0034","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1080\/10428194.2025.2553862","article-title":"Real-world study of tagraxofusp monotherapy in relapsed or refractory blastic plasmacytoid dendritic cell neoplasm","volume":"66","author":"Angelucci","year":"2025","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1016\/j.jtct.2026.08.015_bib0035","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1007\/s00277-025-06493-w","article-title":"Durable outcomes with manageable safety leading to prolonged survival with tagraxofusp for treatment-naive patients with blastic plasmacytoid dendritic cell neoplasm: real world results from a European Named Patient Program","volume":"104","author":"Herling","year":"2025","journal-title":"Ann Hematol"},{"issue":"5","key":"10.1016\/j.jtct.2026.08.015_bib0036","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41409-025-02528-y","article-title":"Survival outcomes between haploidentical stem cell transplantation and chemotherapy for blastic plasmacytoid dendritic cell neoplasm","volume":"60","author":"Zhou","year":"2025","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2026.08.015_bib0037","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ad.2023.09.029","article-title":"Blastic plasmacytoid dendritic cell neoplasm: a single-center experience. clinical characterization, mutational landscape, and clinical outcome of patients undergoing hematopoietic stem cell transplantation intensive therapy","volume":"116","author":"Gil-Lianes","year":"2025","journal-title":"Actas Dermosifiliogr"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2026.08.015_bib0038","doi-asserted-by":"crossref","first-page":"7906","DOI":"10.1182\/blood-2024-204306","article-title":"Hematopoietic cell transplantation (HCT) is an effective treatment for blastic plasmacytoid dendritic cell neoplasm: systematic review and meta-analysis assessing the role of allogeneic and autologous HCT","volume":"144","author":"Mohty","year":"2024","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jtct.2026.08.015_bib0039","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jclinepi.2010.09.011","article-title":"GRADE guidelines: a new series of articles in the journal of clinical epidemiology","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jtct.2026.08.015_bib0040","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-083867","article-title":"Core GRADE 7: principles for moving from evidence to recommendations and decisions","volume":"389","author":"Guyatt","year":"2025","journal-title":"BMJ"},{"issue":"23","key":"10.1016\/j.jtct.2026.08.015_bib0041","first-page":"2813","article-title":"How I treat AML incorporating the updated classifications and guidelines","volume":"141","author":"El Chaer","year":"2023","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2026.08.015_bib0042","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/cyto.b.21932","article-title":"Chronic myelomonocytic leukemia and blastic plasmacytoid dendritic cell neoplasm. A case report and systematic review","volume":"100","author":"Espasa","year":"2021","journal-title":"Cytometry B Clin Cytom"},{"issue":"8","key":"10.1016\/j.jtct.2026.08.015_bib0043","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/s41409-019-0476-6","article-title":"Worldwide network for blood & marrow transplantation (WBMT) special article, challenges facing emerging alternate donor registries","volume":"54","author":"Aljurf","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jtct.2026.08.015_bib0044","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.71464","article-title":"Advancing hematopoietic stem cell transplantation (HSCT) in Africa: a pathway to curing hematological disorders","volume":"8","author":"Ogunniyi","year":"2025","journal-title":"Health Sci Rep"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726006196?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726006196?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T09:42:42Z","timestamp":1789119762000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726006196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":44,"alternative-id":["S2666636726006196"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.08.015","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hematopoietic Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm: Clinical Practice Guidelines From the American Society for Transplantation and Cellular Therapy","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.08.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}